Pharmafile Logo
Pharmafocus logo
Advanced Search

high cholesterol

Showing 13 posts of 13 posts found.

NICE recommends Sanofi, Amgen cholesterol drugs

May 6, 2016
Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …

News

Amgen earns first Japanese nod for PCSK9 inhibitor

January 25, 2016
Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol

The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …

News

NICE rejects Amgen’s Repatha in draft guidance

November 18, 2015
Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol

NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.   

News
Ezetrol

NICE issues draft guidance for MSD’s Ezetrol

October 21, 2015
Sales and Marketing MSD, NICE, cardiovascular disease, ezetimibie, ezetrol, high cholesterol

NICE has published draft guidance recommending MSD’s Ezetrol as an option for some adults with high cholesterol.  The guidance updates …

News
Praluent

Sanofi and Regeneron heart drug Praluent available in UK

October 19, 2015
Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent

Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …

News
lilly_entrance_web

Lilly shares fall as company abandons evacetrapib development

October 13, 2015
Manufacturing and Production evacetrapib, high cholesterol, lilly, phase III, phase III failure

Eli Lilly shares fell by nearly 8% this week as the company announced it will abandon developmenty of the investigational …

News
Praluent

Sanofi and Regeneron given European nod for Praluent

September 28, 2015
Sales and Marketing European Commission, Regeneron, Sanofi, alirocumab, high cholesterol, marketing authorisation, praluent

The European Commission (EC) has approved the marketing authorisation of Sanofi and Regeneron’s cholesterol drug Praluent.  The heart drug is …

News
Amgen

Amgen joins M&A rush with deals for Dezima and Xencor

September 16, 2015
Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation

Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …

News
ESC congress sign

NHS looks to ESC for next-gen heart drug data

August 28, 2015
Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent

New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …

News
Sanofi Regeneron

FDA and EMA approve heart drug Praluent

July 27, 2015
Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent

The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …

News

Amgen’s Repatha wins PCSK9 heart drug race

July 21, 2015
Sales and Marketing Amgen, European Commission, PCKS9, Repatha, evolocumab, high cholesterol

The European Commission has signed off on Amgen’s Repatha, making it the first in a new class of cholesterol-lowering drugs …

News
Logos

Praluent scores positive trial results in Japan

July 9, 2015
Research and Development Japan, PCKS9, Regeneron, Sanofi, heart disease, high cholesterol, praluent

Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …

News

Amarin expands US operations

February 10, 2011
Sales and Marketing AMR101, Amarin, Paul Huff, high cholesterol

Dublin-based biopharmaceutical company Amarin is to increase its US presence by setting up sales and marketing headquarters in New Jersey. …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026